Timothy Cripe, MD, PhD to present on preclinical and preliminary phase 1 clinical safety and efficacy studies of intravenously administered seprehvir, an onocolytic herpes viroimmunotherapeutic.
Timothy Cripe, MD, PhD to present on preclinical and preliminary phase 1 clinical safety and efficacy studies of intravenously administered seprehvir, an onocolytic herpes viroimmunotherapeutic.